Amikacin1) (1) is a typical semi-synthetic aminoglycoside antibiotic widely used clinically.
To examine the antibacterial activity with change of the substituent at C-6" of this antibiotic, we have undertaken to introduce a halogen atom at this position.
As reported, 6"-chloro-6"-deoxykanamycin2) is more active compared to kanamycin while 6"-deoxy-6"-fluoroamikacin3) has decreased activity comparedto amikacin. This result prompted us to prepare 6"-chloro-6"-deoxyamikacin (6) and its analogs.
Tetrakis(iV-terr-butoxycarbonyl)amikacin4) (2) was directly chlorinated with carbon tetrachloride -triphenyrphosphine5) to give the 6"-chloro-6"-deoxy derivative (3) in a moderate yield, meaning that the primary hydroxyl group of 1 at C-6" is fairly selectively replaced by a chlorine atom in the presence of seven secondary hydrxyl groups. Removal of" the iV-protecting group of 3 gave 6"-chloro-6"-deoxyamikacin (4). By a similar route, 6"-deoxy-6"-iodoamikacin (6) was prepared from 2 via the 6"-deoxy-6"-iodo derivative (5). The compound 6 was found to be unstable and gradually degraded on storage. In a similar manner, 6"-chloro-3',6"-dideoxyamikacin (10) was prepared from 3'-deoxyamikacin6) (7) by 7V-ter/-butoxycarbonylation (to give 8) followed by deoxychlorination (to give 9) and deprotection. 6"-Chloro-2',3',6"-trideoxyamikacin (14) was also prepared from 2',3'-di deoxyamikacin7) (ll). iV-Benzyloxycarbonylation of ll gave 12, which was then deoxychlorinated as before to give the 6"-chloro-6"-deoxy derivative (13). Catalytic hydrogenolysis of the iV-protecting groups gave 14 without cleavage of the 6"-chloro atom.
Structures of these semi-synthetic products, 4, 6, 10, and 14 were confirmed by their 13C NMR spectra, in which, C-6" of4, 10, and 14 resonated at 44.6ppm (see Table 1 ), and that of6 at 8.1 ppm, indicating that the halogen atoms were introduced at C-6".
Antibacterial spectra of these products were shown in Table 2 . 6"-Chloro-3/,6''-dideoxyamikacin was most effective, and it could be roughly concluded that introduction of a chlorine at C-6" of amikacin (1) 6"-Deoxy-6"-iodoamikacin (6) 1613 A solution of 5 (100mg) in TFA (0.4ml) was heated at 40°C for 30 minutes. Concentration gave a residue, that was dissolved in 0. 1 Mhydrochloric acid (1 ml) and again concentrated to give a solid of 6, 73.5mg as the hydrochloride.
[a]£°+48°(c 1.7, H2O). TLC of the solid with CHCl3-BuOHEtOH-aq 17% NH3 (2:4:7:7) gave a main spot at Rf 0.22, but attempted column chromatography with silica gel or resin degraded the product giving no pure sample of 6. The product was unstable especially in an alkaline medium, but moderately stable in a neutral or acidic media. XHNMR (D2O-DC1, pD 3) 55.15 (1H, d, J=4Hz, 1"-H), 5 .57
To asolutionof76) (358mg)inDMF-water(1 : 1, 10.5 ml) were added terf-butyl S-(4,6-dimethylpyrimidin-2-y!)thiocarbonate8) (Boc-S, 1.4 g) and triethylamine (2ml), and the mixture was heated at 70°C for 6hours. Addition of aqueous 28% ammonia followed by concentration gave a residue, that was thoroughly washed with water and then with diethyl ether to give a solid of8, 444mg (73%):
[a]g°+98°(c 0.9, MeOH). DEC. 1990 Anal Calcd for C22H42ClN5O10 à" iH2O à" liH2CO3: 
